While high-dose 1,25(OH)2D therapy is limited by hypercalcemia, the non-calcemic analog 20S(OH)D3 has demonstrated efficacy in suppressing arthritis in preclinical models by activating a naturally suppressive receptor on leukemic cells called the Leukemic Immunoglobulin-1 Receptor (LAIR-1), highlighting its potential as a novel treatment. This evidence concerns the gene LAIR1 and arthritic joint disease.